drug_type
RELEVANT_DRUG
intervention_type
Cellular Therapy
drug_description
CAR T cells generated via lentiviral transduction to recognize CD133; IV dose-escalated infusion; targets CD133+ myeloid progenitors/blasts using CAR-mediated T-cell activation and cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous/allogeneic T cells are lentivirally engineered to express a chimeric antigen receptor targeting CD133. CAR engagement of CD133 on myeloid progenitors/blasts triggers MHC-independent T-cell activation, leading to perforin/granzyme-mediated cytotoxicity and cytokine-driven tumor cell clearance.
drug_name
CD133-directed CAR T cells
nct_id_drug_ref
NCT06849921